Equities Analysts Set Expectations for AVXL Q1 Earnings

Anavex Life Sciences Corp. (NASDAQ:AVXL) – Research analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Anavex Life Sciences in a report issued on Tuesday, February 10th. HC Wainwright analyst R. Selvaraju anticipates that the biotechnology company will post earnings per share of ($0.12) for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Anavex Life Sciences’ current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for Anavex Life Sciences’ Q2 2027 earnings at ($0.13) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.15) EPS and FY2027 earnings at ($0.55) EPS.

Several other equities analysts also recently commented on the stock. D. Boral Capital restated a “buy” rating and issued a $24.00 price target on shares of Anavex Life Sciences in a research note on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Anavex Life Sciences in a research note on Monday, December 29th. Finally, Jones Trading downgraded Anavex Life Sciences from a “buy” rating to a “hold” rating in a report on Friday, October 24th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $22.00.

Anavex Life Sciences Stock Performance

Shares of AVXL stock opened at $3.96 on Wednesday. Anavex Life Sciences has a fifty-two week low of $2.86 and a fifty-two week high of $13.99. The company has a 50 day moving average price of $4.30 and a 200 day moving average price of $6.97. The stock has a market capitalization of $353.83 million, a P/E ratio of -8.61 and a beta of 1.21.

Anavex Life Sciences (NASDAQ:AVXL) last issued its quarterly earnings results on Monday, February 9th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.04.

Institutional Trading of Anavex Life Sciences

Several institutional investors have recently modified their holdings of AVXL. Geode Capital Management LLC raised its holdings in Anavex Life Sciences by 2.8% during the second quarter. Geode Capital Management LLC now owns 2,019,795 shares of the biotechnology company’s stock worth $18,624,000 after purchasing an additional 54,985 shares in the last quarter. Two Sigma Investments LP raised its stake in shares of Anavex Life Sciences by 6.5% during the 3rd quarter. Two Sigma Investments LP now owns 1,036,954 shares of the biotechnology company’s stock worth $9,229,000 after buying an additional 63,685 shares in the last quarter. Nwam LLC lifted its holdings in shares of Anavex Life Sciences by 2.4% in the 2nd quarter. Nwam LLC now owns 1,024,479 shares of the biotechnology company’s stock valued at $9,446,000 after buying an additional 24,128 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Anavex Life Sciences by 187.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 872,968 shares of the biotechnology company’s stock valued at $3,108,000 after buying an additional 569,579 shares in the last quarter. Finally, Invesco Ltd. grew its stake in shares of Anavex Life Sciences by 55.8% during the 2nd quarter. Invesco Ltd. now owns 863,959 shares of the biotechnology company’s stock worth $7,966,000 after purchasing an additional 309,605 shares during the period. Hedge funds and other institutional investors own 31.55% of the company’s stock.

Key Stories Impacting Anavex Life Sciences

Here are the key news stories impacting Anavex Life Sciences this week:

• Positive Sentiment: Analysts reaffirm buy ratings and high price targets — HC Wainwright reiterated a “Buy” and a $20 target and provided updated FY‑2027 EPS estimates (FY2027 -$0.55, quarterly EPS around -$0.12 to -$0.15), and D. Boral Capital also kept a “Buy” with a $24 target. Analyst support and improved EPS projections can lift sentiment. Benzinga
• Positive Sentiment: Q1 2026 results beat estimates and show improving cash runway — Anavex reported ($0.06) EPS vs. consensus ($0.10) and reduced quarterly net loss; cash and equivalents rose to $131.7M, giving management an estimated >3 years of runway at current burn. That lowers near‑term financing risk. QuiverQuant press release
• Neutral Sentiment: Corporate milestones and pipeline updates remain in focus — Management outlined regulatory and clinical milestones for blarcamesine (Alzheimer’s, Parkinson’s, Rett syndrome), ANAVEX 3‑71 schizophrenia program progress, and upcoming publications/presentations that could catalyze moves if data or regulatory clarity arrive. Company site
• Neutral Sentiment: Short interest data reported as effectively zero for the most recent update — unlikely to be a near‑term driver given high average trading volume and institutional activity noted in filings.
• Negative Sentiment: EMA issued a negative CHMP opinion on blarcamesine’s EU marketing application — analysts and commentators warn this places the drug in regulatory “purgatory” while Anavex seeks re‑examination, increasing near‑term regulatory risk and uncertainty around approval timing. Seeking Alpha article

About Anavex Life Sciences

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.